Back to results
US 2024/0254235 A1Published application
Compositions and methods for treating lung cancer
OwnerAnthony JARKOWSKI, III, Phillip DENNIS +3inventors
InventorsAnthony JARKOWSKI, III, Phillip DENNIS, Leo TRANI, Michael NEWTON, Norah SHIRE
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for treating locally advanced (Stage III), unresectable non-small-cell lung cancer (NSCLC) with an antibody that inhibits PD-1/PD-L1 activity concurrently with chemoradiation therapy (cCRT).
Claims29
1:
- A method of extending progression-free survival (PFS) in a patient with unresectable non-small-cell lung cancer (NSCLC), the method comprising concurrently treating the patient with an anti-PD-L1 antibody and chemoradiation therapy.
2:
- The method of claim 1, wherein the anti-PD-L1 antibody is human.
3:
- The method of claim 1, wherein the chemoradiation therapy is platinum-based.
4:
- The method of claim 2, wherein the human anti-PD-L1 antibody comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:
- 1 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:
- 2.
5:
- The method of claim 2, wherein the human anti-PD-L1 antibody comprises:
- a VH CDR1 having the amino acid sequence of SEQ ID NO:
- 3;
- and
- a VH CDR2 having the amino acid sequence of SEQ ID NO:
- 4;
- and
- a VH CDR3 having the amino acid sequence of SEQ ID NO:
- 5;
- and
- a VL CDR1 having the amino acid sequence of SEQ ID NO:
- 6;
- and
- a VL CDR2 having the amino acid sequence of SEQ ID NO:
- 7;
- and
- a VL CDR3 having the amino acid sequence of SEQ ID NO:
- 8.
15 more elements
6:
- The method of claim 2, wherein the human anti-PD-L1 antibody is durvalumab, avelumab, atezolizumab, or sugemalimab.
7:
- The method of claim 1, wherein treatment with the anti-PD-L1 antibody comprises administering 1500 mg of the anti-PD-L1 antibody to the patient intravenously every four weeks (Q4W).
8:
- The method of claim 1, wherein the unresectable NSCLC is stage III and/or is locally advanced.
(canceled)
10:
- The method of claim 1, wherein the anti-PD-L1 antibody is administered on the first day of chemoradiation therapy.
11:
- A method of increasing the overall response rate (ORR) in a patient with unresectable non-small-cell lung cancer (NSCLC), the method comprising concurrently treating the patient with an anti-PD-L1 antibody and chemoradiation therapy.
12:
- The method of claim 11, wherein the anti-PD-L1 antibody is human.
13:
- The method of claim 11, wherein the chemoradiation therapy is platinum-based.
14:
- The method of claim 12, wherein the human anti-PD-L1 antibody comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:
- 1 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:
- 2.
15:
- The method of claim 12, wherein the human anti-PD-L1 antibody comprises:
- a VH CDR1 having the amino acid sequence of SEQ ID NO:
- 3;
- and
- a VH CDR2 having the amino acid sequence of SEQ ID NO:
- 4;
- and
- a VH CDR3 having the amino acid sequence of SEQ ID NO:
- 5;
- and
- a VL CDR1 having the amino acid sequence of SEQ ID NO:
- 6;
- and
- a VL CDR2 having the amino acid sequence of SEQ ID NO:
- 7;
- and
- a VL CDR3 having the amino acid sequence of SEQ ID NO:
- 8.
15 more elements
16:
- The method of claim 12, wherein the human anti-PD-L1 antibody is durvalumab, avelumab, atezolizumab, or sugemalimab.
17:
- The method of claim 11, wherein
- treatment with the anti-PD-L1 antibody comprises administering 1500 mg of the anti-PD-L1 antibody to the patient intravenously every four weeks (Q4W).
18:
- The method of claim 11, wherein the unresectable NSCLC is stage III and/or locally advanced.
(canceled)
20:
- The method of claim 11, wherein the anti-PD-L1 antibody is administered on the first day of chemoradiation therapy.
21:
- A method of treating a patient with stage III unresectable non-small-cell lung cancer (NSCLC), the method comprising concurrently treating the patient with an anti-PD-L1 antibody and chemoradiation therapy.
22:
- The method of claim 21, wherein the anti-PD-L1 antibody is human.
23:
- The method of claim 21, wherein the chemoradiation therapy is platinum-based.
24:
- The method of claim 22, wherein the human anti-PD-L1 antibody comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:
- 1 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:
- 2.
25:
- The method of claim 22, wherein the human anti-PD-L1 antibody comprises:
- a VH CDR1 having the amino acid sequence of SEQ ID NO:
- 3;
- and
- a VH CDR2 having the amino acid sequence of SEQ ID NO:
- 4;
- and
- a VH CDR3 having the amino acid sequence of SEQ ID NO:
- 5;
- and
- a VL CDR1 having the amino acid sequence of SEQ ID NO:
- 6;
- and
- a VL CDR2 having the amino acid sequence of SEQ ID NO:
- 7;
- and
- a VL CDR3 having the amino acid sequence of SEQ ID NO:
- 8.
15 more elements
26:
- The method of claim 22, wherein the anti-PD-L1 antibody is durvalumab, avelumab, atezolizumab, or sugemalimab.
27:
- The method of claim 21, wherein treatment with the anti-PD-L1 antibody comprises administering 1500 mg of the anti-PD-L1 antibody to the patient intravenously every four weeks (Q4W).
28:
- The method of claim 21, wherein the anti-PD-L1 antibody is administered on the first day of chemoradiation therapy.
29-43. (canceled)
Dependencies are inferred from the claim text.